This article first appeared on GuruFocus .
Release Date: May 12, 2026
For the complete transcript of the earnings call, please refer to the full earnings call transcript .
Positive Points
-
Sanara MedTech Inc ( NASDAQ:SMTI ) reported a 19% revenue growth in Q1 2026 compared to Q1 2025, driven by increased sales of soft tissue repair products.
-
The company achieved GAAP net profitability with a net income of $0.4 million or $0.04 per diluted share.
-
Gross margin improved by approximately 100 basis points to 93% of net revenue, indicating strong operational efficiency.
-
Sanara MedTech Inc ( NASDAQ:SMTI ) expanded its sales team to 43 representatives and increased its distributor network to over 450, enhancing market reach.
-
The company is not subject to reimbursement risk due to its focus on the surgical setting, providing a predictable and reliable revenue stream.
Negative Points
-
The first quarter is historically the slowest sales period, and a three-day weather-related shutdown in January impacted operations.
-
Operating expenses increased by 12% year-over-year, primarily due to higher selling, general, and administrative expenses.
-
R&D expenses decreased, which could impact future innovation and product development.
-
The company has $46.2 million in long-term debt, slightly up from $46 million at the end of 2025, indicating a need for careful debt management.
-
Higher interest expenses and fees related to term loans and equity method investments contributed to increased other expenses.
Q & A Highlights
Q: Could you break out what was the strongest contributor to the first quarter's outperformance? Was it core accelerate execution by a surge within the Vizient GPO, or did new reps contribute as well? A: The new hires are still in training, and their impact typically takes about six months post-training. The strong performance was due to a clear focus on being a surgical pure play, which was well-received by the team and distributor network. The Vizient contract, although new, is starting to show positive results. Celerate and Biosearch products continue to perform well, with increased penetration in existing and new facilities.
Q: Given the strong execution and tailwinds, why was the guidance left unchanged instead of being raised? A: The goal is to replicate Q4's high volume of procedures. The reorganization of the sales team in early 2025 set us up for long-term success, leading to a slowdown in Q1 2025. We had confidence going into this year, and achieving 19% growth in Q1 was significant. The Q2 guidance of 10% to 14% growth reflects a blend of Q1 and Q2 results, aligning with our overall annual guidance.
Q: Could you elaborate on the initiatives for deepening your competitive moat? A: We focus on clinical evidence for our core products, economic evaluations, and maintaining competitive ASPs. Additionally, we are working on R&D for product enhancements, next-gen products, and expanding our IP portfolio. These efforts strengthen our competitive position.
Q: Are macroeconomic pressures affecting hospital budgets or spending on Sanara products? A: Hospitals are assessing their OR spend, and we are a supply cost within the DRG. Our strong clinical and economic evidence, along with competitive pricing, positions us well. We will continue to build our evidence base to support our technologies.
Q: How are the new sales reps contributing to the business, and what is the timeline for their impact? A: The new sales reps are still undergoing training, both in-house and in the field. It typically takes about six months post-training for them to start making an impact. We expect them, along with additional hires, to contribute to the business by the end of the calendar year.
For the complete transcript of the earnings call, please refer to the full earnings call transcript .
